Brilliant Violet 421™ anti-human IL-10
Description
IL-10 was originally described as Cytokine Synthesis Inhibitory Factor (CSIF) by virtue of its ability to inhibit cytokine production by Th1 clones. IL-10 shares over 80% sequence homology with the Epstein-Barr virus protein BCRFI. The biological activities of IL-10 include inhibition of macrophage-mediated cytokine synthesis, suppression of the delayed type hypersensitivity response, and stimulation of the Th2 cell response, which results in elevated antibody production.
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).Recommended Usage
Each lot of this antibody is quality control tested by intracellular immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤5 microL per million cells or 5 microL per 100 microL of whole blood. It is recommended that the reagent be titrated for optimal performance for each application.
Brilliant Violet 421™ excites at 405 nm and emits at 421 nm. The standard bandpass filter 450/50 nm is recommended for detection. Brilliant Violet 421™ is a trademark of Sirigen Group Ltd.
This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license from Sirigen Inc. The purchase of this product conveys to the buyer a non-transferable right to use the purchased product for research purposes only. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. Patent(s), pending patent applications and foreign equivalents.
References
1. Abrams J, et al. 1992. Immunol. Rev. 127:5. (ELISA Capture, Neut)
2. Gotlieb W, et al. 1992. Cytokine 4:385. (ELISA Capture, Neut)
3. Yssel H, et al. 1992. J. Immunol. 149:2378. (ELISA Capture, Neut)
4. Abrams J. 1995. Curr. Prot. Immunol. John Wiley and Sons New York. Unit 6.20. (ELISA Capture)
5. Burdin N, et al. 1993. J. Exp. Med. 177:295. (ELISA Capture)
6. Klinman D, et al. 1994. Curr. Prot. Immunol. John Wiley and Sons New York. Unit 6.19. (ELISPOT Capture)
7. Schaerli P, et al. 2000. J. Exp. Med. 192:1553.
8. Jason J, et al. 1999. Clin. Diagn. Lab Immunol. 6:73.
9. Akdis CA, et al. 1998. J. Clin. Invest. 102:98. (Neut)
10. Stary G, et al. 2011. J. Immunol. 186:103. PubMed
11. Mason GM, et al. 2012. PNAS. PubMed
12. Smith DR, et al. 1994. Am. J. Pathol. 145:18. (IHC)
13. Stanisic DI, et al. 2014. J Infect Dis. 210:295. PubMed